Deborah advises clients on reimbursement and policy strategy for medical devices, diagnostics, biologics and health services by public and private payers. With more than 25 years of health industry experience, Deborah leverages her deep knowledge and strong industry relationships to deliver strategic, operational and policy consultative services to companies of all sizes, from start-ups to Fortune 100 companies. Due to her deep background in working with clients across the healthcare services spectrum, Deborah has a detailed understanding of the market access process and the historical successes to help healthcare clients with emerging and innovative technologies achieve their goals.
For the past decade, Deborah has worked alongside healthcare innovators to advance their market access goals, including:
Deborah also collaborates with clients pursuing Medicare coding, coverage and payment of their groundbreaking, digitally-enabled healthcare solutions and services, including diagnostic tests and medical devices, artificial intelligence (AI)-powered technologies, remote monitoring tools, and other innovative health services. Her work encompasses assessing the various pathways in federal testing and the requirements needed to obtain additional or incremental payment. Deborah has been successful in obtaining favorable payment rates under the Medicare Clinical Laboratory Fee Schedule, incremental payment in the hospital inpatient and outpatient setting, and procedure, product and diagnosis codes.
Prior to joining McDermottPlus, Deborah was a senior leader at a health technology company focused on the healthcare benefits industry. She also held roles at several consulting firms where she focused on corporate and product strategy for health plans launching new products in the private sector, built health economic models, and analyzed data to assess the effectiveness of federal and state health programs.
“Migrating to Consumer-Directed Healthcare: How to Achieve CDH at Your Organization’s Own Pace”, 28th Annual HR Florida Conference & Expo, September 2006
“Assimilating Health and Wealth: Frontline Perspectives on Employee/Consumer Behavior Influenced by CDH”, Next Generation Health Plan Banking & Administration Management, January 2008
Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction; Prepared for the Office of Health Policy, Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services, September 12, 1997.
Then and Now: Health Plan Movement in the CDH Market; The Healthcare Savings Chronicle, February 2007.
Ten Steps to Implementing a Successful Consumer Directed Health Plan; Benefits and Compensation Digest, October 2007.
CMS Releases FY 2023 IPPS Final Rule
CMS Releases CY 2023 Physician Fee Schedule Proposed Rule
CMS Releases FY 2023 IPPS Proposed Update
Seeking Reimbursement for AI Tech? Five Things to Remember
Key Takeaways from the 2nd Part of FY 2022 IPPS Final Rule
CMS Updates CY 2022 Physician CF: $34.6062
CMS Releases CY 2022 Physician Fee Schedule Final Rule
CMS Releases FY 2022 IPPS Final Rule
Health Policy Breakroom - Ep 77 CY 2022 OPPS Proposed Rule
CMS Releases CY 2022 Physician Fee Schedule Proposed Rule
CMS Releases FY 2022 IPPS Proposed Update
CMS Updates 2021 Physician CF to $34.8931, a 3.3% Reduction from the 2020 CF
Drug Pricing – Trump Administration Announces Most-Favored Nation Drug Pricing Model
Health Policy Breakroom Ep. 51 - 2021 PFS and OPPS Final Rules
UPDATED: CMS Finalizes 10% Payment Cut, Expands Telehealth Services in 2021 Physician Fee Schedule
Show MoreDo not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.
